ArQule — Technical Presentation (June 2010)
24 slides from ArQule's technical presentation, Jun 7, 2010
Slide 1: Results from ARQ 197-209: Global Randomized Placebo-Controlled Phase 2 Trial in NSCLC
Results from ARQ 197-209: A Global Randomized Placebo-Controlled Phase 2 Clinical Trial Comparing Erlotinib Plus ARQ 197 to Erlotinib Plus Placebo in Previously Treated EGFR-Inhibitor Naïve Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer J. H. Schiller, W. L. Akerley, W. Brug
Slide 2: Disclosures
Disclosures: JHS research funding support from Celgene; Genentech; Geron; Novartis; Pfizer; Synta JHS advisory boards and advisory/consulting roles: ArQule; Agennix; Astra Zeneca; Bayer; Biodesix; Daiichi Sankyo; Genentech; GSK; Merck; Novartis; Onyx; Pfizer; Syndax This clinical trial sponsored by
Slide 3: c-MET Receptor Tyrosine Kinase
c-MET Receptor Tyrosine Kinase Implicated in tumor cell migration, invasion, proliferation, and angio-genesis1 Only known high-affinity receptor for hepatocyte growth factor (HGF)1 Birchmeier C and Gherardi E. Trends Cell Biol 1998;8:404–10 Cappuzzo F et al. JCO 2009;27:1667–74 Engelman JA et al. Sc
Slide 4: ARQ 197: a Novel and Selective Tyrosine Kinase Inhibitor
ARQ 197: a Novel and Selective Tyrosine Kinase Inhibitor Non-ATP competitive inhibitor of c-MET Novel mechanism of binding stabilizes inactive conformation of c-MET1 4 Compound demonstrates broad-spectrum, anti-tumor activity in a number of tumor xenograft models (including NSCLC) In vivo anti-tumor
Slide 5: Study Objectives
ARQ 197-209: Study Objectives Primary objective: Compare progression-free survival* (PFS) of patients treated with erlotinib plus ARQ 197 vs erlotinib plus placebo Secondary/exploratory objectives: Evaluate PFS in predefined patient subsets including histology, molecular profile, and other prognosti
Slide 6: Study Design
ARQ 197-209: Study Design Randomized, placebo-controlled, double-blind clinical trial R A N D O M I Z E Erlotinib 150 mg PO QD + Placebo 28-day cycle Erlotinib 150 mg PO QD + ARQ 197 360 mg PO BID 28-day cycle Endpoints 1° PFS 2° ORR, OS Subset analyses Crossover: ORR NSCLC Inoperable locally adv/ m
Slide 7: Key Eligibility Criteria
ARQ 197-209: Key Eligibility Criteria Inoperable locally advanced or metastatic (stage IIIB/IV) NSCLC > 1 prior chemotherapy regimen (including adjuvant therapy) Measurable disease No prior erlotinib or other EGFR inhibiting therapy Clinically stable CNS metastases ECOG performance status 0 to 1 Ade
Slide 8: Statistical Methods
ARQ 197-209: Statistical Methods Sample size powered to detect 68% improvement in PFS (9.4 weeks–15.9 weeks) 120 events (progressions or deaths) required to achieve 80% power for primary endpoint Primary PFS endpoint evaluated using unadjusted log-rank test Cox regression model using a stepwise proc
Slide 9: ARQ 197-209: Demographics and Baseline Characteristics
9 ARQ 197/erlotinib (n=84) Placebo/erlotinib (n=83) Mean age, yrs. (range) 63 (32–81) 62 (23–89) Male 51 (61%) 49 (59%) Caucasian 78 (93%) 80 (96%) Prior chemotherapy regimens 1 50 (60%) 51 (61%) 2 26 (31%) 22 (27%) >2 8 (10%) 10 (12%) Stage at study entry Stage IIIB 8 (10%) 11 (13%) Stage IV 76 (91
Slide 10: Histology and Molecular Characteristics
ARQ 197-209: Histology and Molecular Characteristics 10 ARQ 197/erlotinib (n=84) Placebo/erlotinib (n=83) Histology Adenocarcinoma 45 (54%) 53 (64%) Squamous Cell Carcinoma 26 (31%) 24 (29%) Large Cell 2 (2%) 3 (4%) Unspecified/Other 11 (13%) 3 (4%) Molecular Markers* EGFR mutant 6 (7%) 11 (13%) EGF
Slide 11: Histology and Molecular Characteristics
ARQ 197-209: Histology and Molecular Characteristics 11 ARQ 197/erlotinib (n=84) Placebo/erlotinib (n=83) Histology Adenocarcinoma 45 (54%) 53 (64%) Squamous Cell Carcinoma 26 (31%) 24 (29%) Large Cell 2 (2%) 3 (4%) Unspecified/Other 11 (13%) 3 (4%) Molecular Markers* EGFR mutant 6 (7%) 11 (13%) EGF
Slide 12: Demographics of Patients with Analyzable Tumor Samples
ARQ 197-209: Demographics of Patients with Analyzable Tumor Samples 12 EGFR (n=116) MET (n=141) KRAS (n=109) All patients (n=167) Mean age, years (range) 62.0 (23–89) 62.0 (23–89) 61.2 (23–86) 62.5 (23–89) Male 67 (57.8%) 85 (60.3%) 63 (57.8%) 100 (59.9%) Caucasian 111 (95.7%) 134 (95.0%) 104 (95.4%
Slide 13: ARQ 197-209: Treatment Duration and Discontinuations
13 ARQ 197-209: Treatment Duration and Discontinuations ARQ 197/erlotinib (n=84) Placebo/erlotinib (n=83) Median days on therapy* (range) 101 (4–364) 65 (3–402) Treatment discontinuation 71 (85%) 74 (89%) Disease progression 50 (60%) 58 (70%) Adverse event/withdrawn consent 11 (13%) 9 (11%) Other (i
Slide 14: ARQ 197-209: Additional Grade 3-4 TEAEs of Clinical Relevance
15 ARQ 197-209: Additional Grade 3-4 TEAEs of Clinical Relevance *Resulted in patient death ARQ 197/ erlotinib (n=84) Placebo/ erlotinib (n=83) Interstitial Lung Disease (ILD) 1 (1.2%) 1 (1.2%) Pulmonary Embolism 4 (4.8%) 5 (6.0%) Dyspnea 6 (7.1%) 10 (12.0%) Cardiac Disorders 0 (0%) 3 (3.6%) QT Prol
Slide 15: Progression-Free Survival (ITT Population)
ARQ 197-209: Progression-Free Survival (ITT Population) 16 * Cox regression model PFS also measured by independent radiographic review: - median 15.6 vs. 8.4 wks - unadjusted/adjusted HR= 0.74/0.51 50 20 30 0 10 40 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 Proportion of patients progression-free Tim
Slide 16: Overall Survival (ITT Population)
ARQ 197-209: Overall Survival (ITT Population) 17 HR=0.88 (95% CI: 0.60, 1.3); p=0.50 Adjusted HR=0.88 (95% CI: 0.6, 1.3); p=0.52* Erlotinib + ARQ 197: 36.6 wks (n=84) Erlotinib + Placebo: 29.4 wks (n=83) 0 10 20 30 50 70 40 60 Survival time (weeks) 0.0 0.2 0.4 0.6 0.8 1.0 Proportion of patients sur
Slide 17: PFS and OS in Non-Squamous Cell Histology Patients
ARQ 197-209: PFS and OS in Non-Squamous Cell Histology Patients (n=117) 18 PFS (Investigator Assessed) Overall survival HR=0.72 (95% CI: 0.6, 1.3) P=0.18 Adjusted HR=0.58 (95% CI: 0.34, 0.99) P<0.05* HR=0.71 (95% CI: 0.46, 1.10) P=0.12 Adjusted HR=0.61 (95% CI: 0.47, 0.98) P<0.05* 0 0.0 1.0 0.9 0.8
Slide 18: ARQ 197-209: PFS in Histologic and Molecular Subgroups
5.0 2.0 ARQ 197-209: PFS in Histologic and Molecular Subgroups 20 ARQ197/erlotinib Placebo/erlotinib Unadjusted HR (95% CI) N Median PFS (95% CI, weeks) Squamous Cell 26 / 24 13.7 (8.0–18.1) 8.4 (7.9–21.0) Non-Squamous Cell 58 / 59 18.9 (15.0–31.1) 9.7 (8.0–16.0) c-MET FISH >4 19 / 18 15.4 (8.1–24.4
Slide 19: Overall Response Rate (RECIST 1.0)
ARQ 197-209: Overall Response Rate* (RECIST 1.0) ARQ 197/erlotinib n=73 Placebo/erlotinib n=72 Partial Response** 7 (10%) 5 (7%) Stable Disease 41 (56%) 34 (47%) Disease Control Rate 48 (66%) 39 (54%) 22 * Among patients evaluable for RECIST response ** EGFR status: Combination arm: 3 mutants; 1 WT;
Slide 20: Historic Context of ARQ 197-209 Placebo Arm (BR.21)
Historic Context of ARQ 197-209 Placebo Arm (BR.21) BR.21 Placebo arm (placebo) (n=243) BR.21 Active arm (erlotinib) (n=488) ARQ 197-209 Placebo arm (placebo/erlotinib) (n=83) ARQ 197-209 Active arm (ARQ 197/erlotinib) (n=84) Progression-free survival (mos.) 1.8 2.2 2.3 3.7 Overall survival (mos.) 4
Slide 21: Historic Context of ARQ 197-209 Placebo Arm (BR.21)
Historic Context of ARQ 197-209 Placebo Arm (BR.21) BR.21 Placebo arm (placebo) (n=243) BR.21 Active arm (erlotinib) (n=488) ARQ 197-209 Placebo arm (placebo/erlotinib) (n=83) ARQ 197-209 Active arm (ARQ 197/erlotinib) (n=84) Progression-free survival (mos.) 1.8 2.2 2.3 3.7 Overall survival (mos.) 4
Slide 22: Crossover Patients
ARQ 197-209: Crossover Patients 2 PR2 34 Crossover Patients 23 Evaluable for Response1 1 Baseline + >1 post-baseline scan. Reasons for non-evaluable incl: - Clinical progression (n=4) - Active but haven’t received 1st post-progression scan (n=2) - Death (n=1) - Dosing delay (n=1) - Withdrew consent
Slide 23: Conclusions
ARQ 197-209: Conclusions ARQ 197-erlotinib combination well-tolerated with side-effect profile similar to individual agents RECIST responses observed in both primary double blind analysis and following crossover from placebo to combination therapy Median PFS prolonged with ARQ 197 plus erlotinib vs.
Slide 24: Acknowledgements
Acknowledgements Germany Brugger, W. Eschbach, C. Manegold, C. Reck, M. Sebastian, M. Von Pawel, J. Latvia Ratiani, M. Poland Koralewski, P. Ramlau, R. Sawrycki, P. Serwatowski, P. Szczesna, A. Russia Byakhov, M. Moiseyenko, V. Orlov, S. Severtsev, A. Ukraine Shparyk, Y. USA Akerley, W. Badarinath,